Table 2.
Clinical characteristics of the CRS-2 patients with elevated and normal-range urinary podocin/Cr ratios
| Elevated podocin/Cr ratio (n = 11) | Normal-range podocin/Cr ratio (n = 16) | p value | |
|---|---|---|---|
| Characteristics | |||
| Age, years | 58 ± 14 | 57 ± 9 | 0.80 |
| Male | 6 (55) | 9 (56) | 0.93 |
| White/African-American | 5 (45)/6 (55) | 3 (16)/13 (84) | 0.07 |
| Medical history | |||
| Diabetes mellitus | 3 (27) | 7 (43) | 0.40 |
| Hypertension | 9 (81) | 12 (81) | 0.68 |
| Atrial fibrillation | 4 (36) | 6 (37) | 0.95 |
| Ischemic etiology | 3 (27) | 5 (31) | 0.94 |
| Cr, mg/dl | 1.37 ± 0.4 | 1.59 ± 0.67 | 0.34 |
| Proteinuria, % | 54 | 56 | 0.71 |
| eGFR, ml/min/1.73 m2 | 48 ± 9 | 46 ± 17 | 0.75 |
| Treatment | |||
| β-Adrenergic blockade | 11 (100) | 16 (100) | |
| ACEI | 8 (72) | 12 (75) | 0.90 |
| ARB | 1 (9) | 5 (31) | 0.17 |
| ARA | 1 (9) | 6 (37) | 0.10 |
| Double therapy1 | 1 (9) | 7 (44) | 0.05 |
| Double therapy with either ACEI or ARB at ≥50% of the max. dose | 0 (0) | 5 (31) | 0.04 |
| ICD | 8 (72) | 11 (68) | 0.82 |
Values are means ± SD or n (%), unless otherwise indicated.
ICD = Implantable cardioverter defibrillator.
1
Combined therapy consisting of at least two of the following: ACEI, ARA, or ARB.